☆ 4.7 Letter

Frequency and prognostic impact of casein kinase 1A1 mutations in MDS patients with deletion of chromosome 5q

LEUKEMIA (2015)

期刊

LEUKEMIA

卷 29, 期 9, 页码 1942-1945

出版社

NATURE PUBLISHING GROUP

DOI: 10.1038/leu.2015.49

关键词

-

类别

Oncology Hematology

向作者/读者索取更多资源

Protocol

Reagent

作者

我是这篇论文的作者

点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7

评分不足

次要评分

新颖性

-

重要性

-

科学严谨性

-

评价这篇论文

推荐

Article Hematology

Genetic barcoding systematically compares genes in del(5q) MDS and reveals a central role for CSNK1A1 in clonal expansion

Ursula S. A. Stalmann, Fabio Ticconi, Inge A. M. Snoeren, Ronghui Li, Helene F. E. Gleitz, Glenn S. Cowley, Marie E. McConkey, Aaron B. Wong, Stephani Schmitz, Stijn N. R. Fuchs, Shubhankar Sood, Nils B. Leimkuehler, Sergio Martinez-Hoyer, Bella Banjanin, David Root, Tim H. Bruemmendorf, Juliette E. Pearce, Andreas Schuppert, Eric M. J. Bindels, Marieke A. Essers, Dirk Heckl, Thomas Stiehl, Ivan G. Costa, Benjamin L. Ebert, Rebekka K. Schneider

Summary: Genetic haploinsufficiency plays a crucial role in the clonal dominance of 5q-HSCs, providing a unique competitive advantage through increased HSC self-renewal and proliferation capacity, as well as increased fitness under inflammatory stress.

BLOOD ADVANCES (2022)

添加到收藏夹

Review Oncology

Myelodysplastic Syndromes with Isolated del(5q): Value of Molecular Alterations for Diagnostic and Prognostic Assessment

Pamela Acha, Mar Mallo, Francesc Sole

Summary: Myelodysplastic syndromes with isolated del(5q) are a subtype of MDS defined by cytogenetic alteration. This review summarizes the current knowledge of the molecular background of MDS with isolated del(5q), focusing on the clinical and prognostic relevance of cytogenetic alterations and somatic mutations.

CANCERS (2022)

添加到收藏夹

Review Oncology

Novel Molecular Mechanism of Lenalidomide in Myeloid Malignancies Independent of Deletion of Chromosome 5q

Isaac Park, Tra Mi Phan, Jing Fang

Summary: Lenalidomide and other IMiDs have shown clinical efficacy in certain subtypes of hematologic malignancies, such as multiple myeloma and lower-risk MDS with del(5q). Despite superior clinical response, relapse and resistance are still challenges in IMiD therapy. Recent studies have revealed novel molecular mechanisms of IMiD-based anti-tumor therapy.

CANCERS (2021)

添加到收藏夹

Article Oncology

Prognostic significance of serial molecular annotation in myelodysplastic syndromes (MDS) and secondary acute myeloid leukemia (sAML)

Seongseok Yun, Susan M. Geyer, Rami S. Komrokji, Najla H. Al Ali, Jinming Song, Mohammad Hussaini, Kendra L. Sweet, Jeffrey E. Lancet, Alan F. List, Eric Padron, David A. Sallman

Summary: The clinical relevance of serial molecular annotation during treatment in patients with myelodysplastic syndrome (MDS) or secondary acute myeloid leukemia (sAML) was investigated. The study found that mutation clearance (NGS-) was associated with improved overall survival (OS) and represented a potential biomarker for treatment outcomes, highlighting the importance of serial NGS evaluations during treatment.

LEUKEMIA (2021)

添加到收藏夹

Article Oncology

Therapeutic Outcomes and Prognostic Impact of Gene Mutations Including TP53 and SF3B1 in Patients with Del(5q) Myelodysplastic Syndromes (MDS)

Onyee Chan, Najla Al Ali, David Sallman, Eric Padron, Jeffrey Lancet, Rami Komrokji

Summary: This study retrospectively reviewed 132 del(5q) MDS patients and described the treatment outcomes and prognostic impact of gene mutations. The study found that lenalidomide was an effective treatment for del(5q) MDS patients, but hypomethylating agents after lenalidomide failure did not provide survival advantage. There was no significant difference in overall survival between patients with or without TP53 mutations, but patients with SF3B1 mutations had inferior survivals.

CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2022)

添加到收藏夹

Review Medicine, General & Internal

MDS with deletion 5q - a distinct subtype of myelodysplastic syndromes

Christian Matthias Wilk, Jeroen Simon Goede

Summary: Deletion of the long arm of chromosome 5 (del(5q)) is a common anomaly in myelodysplastic syndromes, which has specific pathophysiology and treatment options. MDS patients with isolated del(5q) have a low risk profile and can be treated with lenalidomide. It is important to differentiate isolated del(5q) from MDS with an anomaly on the long arm of chromosome 5 and additional mutations, which are classified as high-risk forms of MDS.

THERAPEUTISCHE UMSCHAU (2022)

添加到收藏夹

Article Hematology

Myelodysplastic syndromes with 20q deletion: incidence, prognostic value and impact on response to azacitidine of ASXL1 chromosomal deletion and genetic mutations

Ivan Martin, Eva Villamon, Rosario Abellan, Maria Jose Calasanz, Aroa Irigoyen, Guillermo Sanz, Esperanza Such, Elvira Mora, Miriam Gutierrez, Rosa Collado, Rocio Garcia-Serra, Miriam Vara, Ma Laura Blanco, Itziar Oiartzabal, Sara alvarez, Teresa Bernal, Isabel Granada, Blanca Xicoy, Andres Jerez, Marisa Calabuig, Rosana Diez, Angela Gil, Maria Diez-Campelo, Carlos Solano, Mar Tormo

Summary: Chromosomal alterations and genetic mutations of the ASXL1 gene are common in MDS patients with del(20q), and are associated with shorter overall survival and a higher risk of AML progression. ASXL1 alterations also lead to a poorer response to azacitidine (AZA) treatment.

BRITISH JOURNAL OF HAEMATOLOGY (2021)

添加到收藏夹

Article Genetics & Heredity

Contribution of whole genome sequencing in the molecular diagnosis of mosaic partial deletion of the NF1 gene in neurofibromatosis type

Laurence Pacot, Valerie Pelletier, Albain Chansavang, Audrey Briand-Suleau, Cyril Burin des Roziers, Audrey Coustier, Theodora Maillard, Nicolas Vaucouleur, Lucie Orhant, Cecile Barbance, Alban Lermine, Nadim Hamzaoui, Djihad Hadjadj, Ingrid Laurendeau, Laila El Khattabi, Juliette Nectoux, Michel Vidaud, Beatrice Parfait, Helene Dollfus, Eric Pasmant, Dominique Vidaud

Summary: This case report highlights the importance of whole genome sequencing (WGS) in diagnosing patients with neurofibromatosis type 1 (NF1). WGS can detect structural variants, including copy number variants, that may be missed by other methods. By detecting the pathogenic variant in the cell-free DNA of the patient's pregnant partner, targeted genetic counseling and non-invasive prenatal diagnosis were made possible.

HUMAN GENETICS (2023)

添加到收藏夹

Article Genetics & Heredity

Radiotherapy is associated with a deletion signature that contributes to poor outcomes in patients with cancer

Emre Kocakavuk, Kevin J. Anderson, Frederick S. Varn, Kevin C. Johnson, Samirkumar B. Amin, Erik P. Sulman, Martijn P. Lolkema, Floris P. Barthel, Roel G. W. Verhaak

Summary: Ionizing radiation induces DNA damage and increases small and large deletions in tumor genomes. Effective repair of radiation-induced DNA damage is associated with worse clinical outcomes, and these genomic changes can be used to predict sensitivity to radiation therapy in recurrent cancer.

NATURE GENETICS (2021)

添加到收藏夹

Article Hematology

Interplay of TP53 allelic state, blast count, and complex karyotype on survival of patients with AML and MDS

Anna Stengel, Manja Meggendorfer, Wencke Walter, Constance Baer, Niroshan Nadarajah, Stephan Hutter, Wolfgang Kern, Torsten Haferlach, Claudia Haferlach

Summary: Several clinical and genetic factors, including complex karyotype, TP53 allelic state, and blast count, impact overall survival in myelodysplastic neoplasms and acute myeloid leukemia. TP53 double-hit events are the strongest prognostic factor, while blast count also independently influences overall survival.

BLOOD ADVANCES (2023)

添加到收藏夹

Article Multidisciplinary Sciences

BRAFΔß3-αC in-frame deletion mutants differ in their dimerization propensity, HSP90 dependence, and druggability

Manuel Lauinger, Daniel Christen, Rhena F. U. Klar, Carole Roubaty, Christoph E. Heilig, Michael Stumpe, Jennifer J. Knox, Nikolina Radulovich, Laura Tamblyn, Irene Y. Xie, Peter Horak, Andrea Forschner, Michael Bitzer, Uwe A. Wittel, Melanie Boerries, Claudia R. Ball, Christoph Heining, Hanno Glimm, Martina Froehlich, Daniel Huebschmann, Steven Gallinger, Ralph Fritsch, Stefan Froehling, Grainne M. O'Kane, Joern Dengjel, Tilman Brummer

Summary: This study functionally characterizes BRAF exon 12 deletions and compares them with other BRAF ss 3-alpha C mutants. It demonstrates that BRAF(Delta ss 3-alpha C) deletion mutants form stable dimers and multiprotein complexes, and their dimerization is necessary. Some mutants with aromatic amino acid insertions at the deletion junction exhibit resistance to monomer-favoring RAF inhibitors while being sensitive to dimer-favoring inhibitors.

SCIENCE ADVANCES (2023)

添加到收藏夹

Article Genetics & Heredity

Philadelphia chromosome positive chronic myeloid leukemia with 5q deletion at diagnosis

Ahmed Maseh Haidary, Zeeshan Ansar Ahmed, Jamshid Abdul-Ghafar, Soma Rahmani, Sarah Noor, Farahnaz Erfani, Maryam Ahmad, Naeem Lakanwall, Haider Ali Malakzai, Abdul Sami Ibrahimkhil, Esmatullah Esmat, Mujtaba Haidari, Nimattullah Yousufzai, Samuel Sharif, Abdul Hadi Saqib

Summary: 5q deletions are rare in CML, with reported cases either linked to tyrosine kinase inhibitor therapy or post allogeneic stem cell transplantation. This case represents the first reported instance of Ph positive CML accompanied by a 5q deletion.

MOLECULAR CYTOGENETICS (2021)

添加到收藏夹

Article Oncology

Wilms' tumor 1 expression combined with genetic mutations for prognostic assessment in MDS

Danqi Pan, Wenshu Zhao, Qianli Jiang, Changxin Yin, Han He, Libin Liao, Jieyu Ye, Min Dai

Summary: Overexpression of Wilms' tumor (WT1) is frequently observed in myelodysplastic syndrome (MDS) and has been proposed as a prognostic marker. This study retrospectively assessed the relationship between WT1 levels and preexisting prognostic factors to investigate its prognostic role in different contexts. The results showed that WT1 expression was correlated with WHO 2016 classification and IPSS-R stratification. It also had different associations with specific gene mutations, and its prognostic effect varied depending on TP53 mutation status.

LEUKEMIA & LYMPHOMA (2023)

添加到收藏夹

Article Oncology

Incidence and prognostic impact of U2AF1 mutations and other gene alterations in myelodysplastic neoplasms with isolated 20q deletion

Martin I. Castillo, Villamon E. Ribate, Calabuig M. Munoz, Sanz G. Santillana, Such E. Taboada, Mora E. Castera, Calasanz M. J. Abinzano, Irigoyen A. Barranco, Collado R. Nieto, Vara M. Pampliega, M. L. Blanco, Alvarez S. de Andres, Perez J. de Oteyza, Bernal T. del Castillo, Granada I. Font, Jerez A. Cayuela, M. Diez-Campelo, Abellan R. Sanchez, Solano C. Vercet, Tormo M. Diaz

Summary: This study analyzes different molecular variables in 100 MDS patients with isolated del(20q), and finds that U2AF1 mutations and other alterations have a negative prognostic impact on patients. Additionally, mutations in the ASXL1 gene are identified as a prognostic marker, which could benefit patients in receiving earlier treatment.

CANCER MEDICINE (2023)

添加到收藏夹

Article Medicine, Research & Experimental

Tumor genotype dictates radiosensitization after Atm deletion in primary brainstem glioma models

Katherine Deland, Bryce F. Starr, Joshua S. Mercer, Jovita Byemerwa, Donna M. Crabtree, Nerissa T. Williams, Lixia Luo, Yan Ma, Mark Chen, Oren J. Becher, David G. Kirsch

Summary: The study suggests that deleting Atm in DIPG models can enhance tumor radiosensitivity, especially in the absence of p53. Mice with p53 wild-type tumors also showed improved survival after radiotherapy, regardless of Atm deletion. Tumor genotype may determine whether inhibiting ATM during radiotherapy is an effective approach.

JOURNAL OF CLINICAL INVESTIGATION (2021)

添加到收藏夹

Article Hematology

Impact of IDH1 and IDH2 mutation detection at diagnosis and in remission in patients with AML receiving allogeneic transplantation

Marius Bill, Madlen Jentzsch, Lara Bischof, Jessica Kohlschmidt, Juliane Grimm, Laura Katharina Schmalbrock, Donata Backhaus, Dominic Brauer, Karoline Goldmann, Georg -Nikolaus Franke, Vladan Vucinic, Dietger Niederwieser, Alice S. Mims, Uwe Platzbecker, Ann-Kathrin Eisfeld, Sebastian Schwind

Summary: Somatic mutations in IDH1 and IDH2 genes are common in AML. The presence of IDH mutations may not significantly impact the prognosis of AML patients consolidated by HSCT, but specific mutation locations (IDH1 R132, IDH2 R140, and IDH2 R172) and mutation dynamics do affect the risk of relapse. IDH2 R140 mutations behave more like clonal hematopoiesis-related aberrations, while IDH1 R132 and IDH2 R172 harbor AML disease-specific features.

BLOOD ADVANCES (2023)

添加到收藏夹

Article Hematology

Characteristics and outcome of patients with acute myeloid leukemia and trisomy 4

Sabine Kayser, David Martinez-Cuadron, Maher Hanoun, Friedrich Stoelzel, Cristina Gil, H. Christian Reinhardt, Eliana Aguiar, Kerstin Schaefer-Eckart, Juan Miguel Bergua Burgues, Bjoern Steffen, Teresa Bernal, Stefan W. Krause, Rosalia Riaza, Christoph Schliemann, Jose Cervera, Martin Kaufmann, Laura Torres-Minana, Mathias Haenel, Evelyn Acuna-Cruz, Edgar Jost, Jesus Lorenzo Algarra, Martina Crysandt, Lars Fransecky, Javier Cornago-Navascues, Sabrina Kraus, Joaquin Martinez-Lopez, Hermann Einsele, Dirk Niemann, Andreas Neubauer, Ruth Seggewiss-Bernhardt, Sebastian Scholl, Stefan A. Klein, Christoph Schmid, Markus Schaich, Martin Schmidt-Hieber, Sven Zukunft, Anthony D. Ho, Uwe Platzbecker, Claudia D. Baldus, Carsten Mueller-Tidow, Christian Thiede, Martin Bornhaeuser, Hubert Serve, Mark J. Levis, Pau Montesinos, Christoph Roellig, Richard F. Schlenk

Summary: This retrospective study analyzed 125 patients with acute myeloid leukemia and trisomy 4. Among them, 22% had trisomy 4 as the sole abnormality, while the remaining 78% had additional abnormalities. Patients with trisomy 4 as their sole abnormality had a high complete remission rate, but allogeneic hematopoietic cell transplantation did not improve overall survival.

HAEMATOLOGICA (2023)

添加到收藏夹

Article Hematology

Prediction of complete remission and survival in acute myeloid leukemia using supervised machine learning

Jan-Niklas Eckardt, Christoph Rillig, Klaus Metzeler, Michael Kramer, Sebastian Stasik, Julia-Annabell Georgi, Peter Heisig, Karsten Spiekermann, Utz Krug, Jan Braess, Dennis Girlich, Cristina M. Sauerland, Bernhard Woermann, Tobias Herold, Wolfgang E. Berdel, Wolfgang Hiddemann, Frank Kroschinsky, Johannes Schetelig, Uwe Platzbecker, Carsten Mueller-Tidow, Tim Sauer, Hubert Serve, Claudia Baldus, Kerstin Schaefer-Eckart, Martin Kaufmann, Stefan Krause, Mathias Haenel, Christoph Schliemann, Maher Hanoun, Christian Thiede, Martin Bornhaeuser, Karsten Wendt, Jan Moritz Middeke

Summary: This study used machine learning models to predict complete remission and 2-year overall survival in AML patients, incorporating clinical, laboratory, cytogenetic and molecular genetic data. The predictive features for complete remission included gene mutations such as CEBPA, NPM1, FLT3-ITD, etc., as well as certain clinical indicators. Predictive markers for 2-year overall survival included gene mutations such as CEBPA, FLT3-ITD, white blood cell count, etc.

HAEMATOLOGICA (2023)

添加到收藏夹

Article Allergy

Expression and regulation of Siglec-6 (CD327) on human mast cells and basophils

Dubravka Smiljkovic, Harald Herrmann, Irina Sadovnik, Susanne Gamperl, Daniela Berger, Gabriele Stefanzl, Gregor Eisenwort, Gregor Hoermann, Sonja Kopanja, Yulia Dorofeeva, Margarete Focke-Tejkl, Peter Jaksch, Konrad Hoetzenecker, Zsolt Szepfalusi, Rudolf Valenta, Michel Arock, Peter Valent

Summary: Siglec-6 is identified as a surface antigen specifically expressed on human MC and basophils. Its expression is dynamically regulated and varies depending on cell types and activation factors. Understanding the expression changes of Siglec-6 provides insights into the function of MC and basophils in allergic reactions.

JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2023)

添加到收藏夹

Review Allergy

Proposed refined diagnostic criteria and classification of eosinophil disorders and related syndromes

Peter Valent, Amy D. Klion, Florence Roufosse, Dagmar Simon, Georgia Metzgeroth, Kristin M. Leiferman, Juliana Schwaab, Joseph H. Butterfield, Wolfgang R. Sperr, Karl Sotlar, Peter Vandenberghe, Gregor Hoermann, Torsten Haferlach, Richard Moriggl, Tracy George, Cem Akin, Bruce S. Bochner, Jason Gotlib, Andreas Reiter, Hans-Peter Horny, Michel Arock, Hans-Uwe Simon, Gerald J. Gleich

Summary: Eosinophilia and eosinophil activation are common in various diseases. They can lead to hypereosinophilia and hypereosinophilic syndrome, which can cause organ damage. The classification and criteria for these conditions have been widely accepted and regarded as standard since 2012. However, new developments in the field have created a need to update these criteria. A recent working conference on eosinophil disorders discussed new markers and concepts, aiming to improve the diagnosis and management of patients with hypereosinophilia and hypereosinophilic syndrome.

ALLERGY (2023)

添加到收藏夹

Article Hematology

Incidence of symptomatic Covid-19 infections in patients with mastocytosis and chronic myeloid leukemia: A comparison with the general Austrian population

Irene Graf, Susanne Herndlhofer, Michael Kundi, Georg Greiner, Martina Sperr, Emir Hadzijusufovic, Peter Valent, Wolfgang R. Sperr

Summary: This study analyzed the prevalence of Covid-19 infections in patients with mastocytosis compared to patients with chronic myeloid leukemia (CML) and the general Austrian population. The results showed that the prevalence of Covid-19 infections in mastocytosis patients was 2.2%, which was not significantly different from CML patients and the general population.

EUROPEAN JOURNAL OF HAEMATOLOGY (2023)

添加到收藏夹

Letter Hematology

An agenda to advance research in myelodysplastic syndromes: a TOP 10 priority list from the first international workshop in MDS

Maximilian Stahl, Omar Abdel-Wahab, Andrew H. Wei, Michael R. Savona, Mina L. Xu, Zhuoer Xie, Justin Taylor, Daniel Starczynowski, Guillermo F. Sanz, David A. Sallman, Valeria Santini, Gail J. Roboz, Mrinal M. Patnaik, Eric Padron, Olatoyosi Odenike, Aziz Nazha, Stephen D. Nimer, Ravindra Majeti, Richard F. Little, Steven Gore, Alan F. List, Vijay Kutchroo, Rami S. Komrokji, Tae Kon Kim, Nina Kim, Christopher S. Hourigan, Robert P. Hasserjian, Stephanie Halene, Elizabeth A. Griffiths, Peter L. Greenberg, Maria Figueroa, Pierre Fenaux, Fabio Efficace, Amy E. DeZern, Matteo G. Della Porta, Naval G. Daver, Jane E. Churpek, Hetty E. Carraway, Andrew M. Brunner, Uma Borate, John M. Bennett, Rafael Bejar, Jacqueline Boultwood, Sanam Loghavi, Jan Philipp Bewersdorf, Uwe Platzbecker, David P. Steensma, Mikkael A. Sekeres, Rena J. Buckstein, Amer M. Zeidan

BLOOD ADVANCES (2023)

添加到收藏夹

Article Hematology

Improved benefit of continuing luspatercept therapy: sub-analysis of patients with lower-risk MDS in the MEDALIST study

Ulrich Germing, Pierre Fenaux, Uwe Platzbecker, Rena Buckstein, Valeria Santini, Maria Diez-Campelo, Aylin Yucel, Derek Tang, Shannon Fabre, George Zhang, Roberto Zoffoli, Xianwei Ha, Dimana Miteva, Christina Hughes, Rami S. S. Komrokji, Amer M. M. Zeidan, Guillermo Garcia-Manero

Summary: Red blood cell transfusion independence (RBC-TI) can be achieved more effectively with luspatercept compared to placebo in the first 24 weeks of treatment for lower-risk myelodysplastic syndromes with ring sideroblasts. Long-term analysis also suggests that continuing luspatercept treatment beyond week 25 can provide additional clinical benefits for initial nonresponders.

ANNALS OF HEMATOLOGY (2023)

添加到收藏夹

Article Hematology

Overlapping features of therapy-related and de novo NPM1-mutated AML

Jad Othman, Manja Meggendorfer, Enrico Tiacci, Christian Thiede, Richard Schlenk, Richard Dillon, Sebastian Stasik, Alessandra Venanzi, Sarah Bertoli, Eric Delabesse, Pierre-Yves Dumas, Arnaud Pigneux, Audrey Bidet, Amanda F. Gilkes, Ian Thomas, Maria Teresa Voso, Alessandro Rambaldi, Lorenzo Brunetti, Vincenzo M. Perriello, Vibeke Andresen, Bjorn T. Gjertsen, Maria Paola Martelli, Christian Recher, Christoph Roellig, Martin Bornhaeuser, Hubert Serve, Carsten Mueller-Tidow, Claudia D. Baldus, Tortsten Haferlach, Nigel Russell, Brunangelo Falini

Summary: The characteristics of therapy-related NPM1-mutated AML (t-NPM1 AML) were found to be similar to de novo NPM1-mutated AML (dn-NPM1 AML) in terms of genetics, transcriptional profile, and clinical outcomes. However, t-NPM1 AML showed better overall survival and relapse-free survival compared to t-AML.

BLOOD (2023)

添加到收藏夹

Article Biochemistry & Molecular Biology

Clonal Hematopoiesis Mutations Are Present in Atherosclerotic Lesions in Peripheral Artery Disease

Petra Buettner, Julia Boettner, Knut Krohn, Ronny Baber, Uwe Platzbecker, Michael Cross, Steffen Desch, Holger Thiele, Sabine Steiner, Dierk Scheinert, Klaus H. Metzeler, Daniela Branzan

Summary: In this pilot study, it was found that clonal hematopoiesis (CH)-associated mutations can be detected in both peripheral blood cells and tissues associated with atherosclerosis, suggesting a potential impact on disease physiology.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

添加到收藏夹

Article Oncology

Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes

Elisabetta Sauta, Marie Robin, Matteo Bersanelli, Erica Travaglino, Manja Meggendorfer, Lin-Pierre Zhao, Juan Carlos Caballero Berrocal, Claudia Sala, Giulia Maggioni, Massimo Bernardi, Carmen Di Grazia, Luca Vago, Giulia Rivoli, Lorenza Borin, Saverio D'Amico, Cristina Astrid Tentori, Marta Ubezio, Alessia Campagna, Antonio Russo, Daniele Mannina, Luca Lanino, Patrizia Chiusolo, Luisa Giaccone, Maria Teresa Voso, Marta Riva, Esther Natalie Oliva, Matteo Zampini, Elena Riva, Olivier Nibourel, Marilena Bicchieri, Niccolo' Bolli, Alessandro Rambaldi, Francesco Passamonti, Victor Savevski, Armando Santoro, Ulrich Germing, Shahram Kordasti, Valeria Santini, Maria Diez-Campelo, Guillermo Sanz, Francesc Sole, Wolfgang Kern, Uwe Platzbecker, Lionel Ades, Pierre Fenaux, Torsten Haferlach, Gastone Castellani, Matteo Giovanni Della Porta

Summary: The study validates the effectiveness of the Molecular International Prognostic Scoring System (IPSS-M) in predicting clinical outcomes of patients with myelodysplastic syndromes (MDS). IPSS-M improves the prognostic discrimination of the Revised International Prognostic Scoring System (IPSS-R) and enhances the accuracy of selecting candidates for hematopoietic stem cell transplantation (HSCT).

JOURNAL OF CLINICAL ONCOLOGY (2023)

添加到收藏夹

Article Clinical Neurology

Case report: Treatment of advanced CSF1-receptor associated leukoencephalopathy with hematopoietic stem cell transplant

Caroline G. Bergner, Lisa Schaefer, Vladan Vucinic, Birthe Schetschorke, Julia Lier, Cordula Scherlach, Michael Rullmann, Osama Sabri, Joseph Classen, Uwe Platzbecker, Joern-Sven Kuehl, Henryk Barthel, Wolfgang Koehler, Georg-Nikolaus Franke

Summary: CSF1R-related leukoencephalopathy is a rare genetic disorder causing white matter dementia, and hematopoietic stem cell transplant might be a promising treatment. However, it is unclear which patients are suitable for this treatment and there is a lack of imaging biomarkers for lasting structural damage.

FRONTIERS IN NEUROLOGY (2023)

添加到收藏夹

Article Oncology

Allogeneic Hematopoietic Cell Transplantation vs Standard Consolidation Chemotherapy in Patients With Intermediate-Risk Acute Myeloid Leukemia A Randomized Clinical Trial

Martin Bornhaeuser, Christoph Schliemann, Johannes Schetelig, Christoph Roellig, Michael Kramer, Bertram Glass, Uwe Platzbecker, Andreas Burchert, Mathias Haenel, Lutz P. Mueller, Stefan Klein, Gesine Bug, Dietrich Beelen, Wolf Roesler, Kerstin Schaefer-Eckart, Christoph Schmid, Edgar Jost, Georg Lenz, Johanna Tischer, Karsten Spiekermann, Markus Pfirrmann, Hubert Serve, Friedrich Stoelzel, Nael Alakel, Jan Moritz Middeke, Christian Thiede, Gerhard Ehninger, Wolfgang E. Berdel, Matthias Stelljes

Summary: This study explored the optimal therapy for patients with intermediate-risk AML after first complete remission, and found that primary allogeneic HCT was not associated with superior overall survival compared with consolidation chemotherapy.

JAMA ONCOLOGY (2023)

添加到收藏夹

Article Oncology

Clinical Implications of the FLT3-ITD Allelic Ratio in Acute Myeloid Leukemia in the Context of an Allogeneic Stem Cell Transplantation

Madlen Jentzsch, Lara Bischof, Dominic Brauer, Donata Backhaus, Jule Ussmann, Georg-Nikolaus Franke, Vladan Vucinic, Uwe Platzbecker, Sebastian Schwind

Summary: The presence and allelic ratio of FLT3-ITD have been recognized as prognostic factors in acute myeloid leukemia (AML), but their impact on patient outcomes after allogeneic hematopoietic stem cell transplantation (HSCT) is not well understood. This study found that the FLT3-ITD allelic ratio did not significantly affect survival in patients undergoing HSCT, but highlighted the importance of pre-HSCT measurable residual disease (MRD) as a prognostic factor.

CANCERS (2023)

添加到收藏夹

Letter Hematology

Primary Cancer Matters in Therapy-related Myeloid Neoplasm Patients Receiving Allogeneic Hematopoietic Cell Transplantation: A Study From the Chronic Malignancies Working Party of the EBMT

Marie Robin, Liesbeth C. de Wreede, Thomas Schroeder, Friedrich Stoelzel, Nicolaus Kroeger, Linda Koster, Uwe Platzbecker, Juergen Finke, Arnold Ganser, Didier Blaise, Fabio Ciceri, Johan Maertens, Helene Labussiere Wallet, Junfeng Wang, Patrice Chevallier, Jakob Passweg, Jan J. Cornelissen, Stephanie Nguyen, Edouard Forcade, Amandine Charbonnier, Francesca Bonifazi, Patrick Hayden, Donal P. McLornan, Ibrahim Yakoub-Agha

HEMASPHERE (2023)

添加到收藏夹

暂无数据

© Peeref 2019-2024. All rights reserved.